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Abstract
Background: Although both smoking and respiratory complaints are very common, tools to 
improve diagnostic accuracy are scarce in primary care. This study aimed to reveal what 
inflammatory patterns prevail in clinically established diagnosis groups, and what factors are 
associated with eosinophilia.
Method: Induced sputum and blood plasma of 59 primary care patients with COPD (n = l7), 
asthma (n = l l), chronic bronchitis (CB, n = l4) and smokers with no respiratory complaints 
('healthy smokers', n = l7) were collected, as well as lung function, smoking history and clinical 
work-up. Patterns of inflammatory markers per clinical diagnosis and factors associated with 
eosinophilia were analyzed by multiple regression analyses, the differences expressed in odds ratios 
(OR) with 95% confidence intervals.
Results: Multivariately, COPD was significantly associated with raised plasma-LBP (OR l.2 [l.04— 
l.37]) and sTNF-R55 in sputum (OR l.0 l [ l .0 0 l- l.0 l] ) ,  while HS expressed significantly lowered 
plasma-LBP (OR 0.8 [0.72-0.95]). Asthma was characterized by higher sputum eosinophilic counts 
(OR l.3 [l.05-l.54 ]), while CB showed a significantly higher proportion of sputum lymphocytic 
counts (OR l.5 [ l . l 2—1.9]). Sputum eosinophilia was significantly associated with reversibility after 
adjusting for smoking, lung function, age, gender and allergy.
Conclusion: Patterns of inflammatory markers in a panel of blood plasma and sputum cells and 
mediators were discernable in clinical diagnosis groups of respiratory disease. COPD and so-called 
healthy smokers showed consistent opposite associations with plasma LBP, while chronic 
bronchitics showed relatively predominant lymphocytic inflammation compared to  other diagnosis 
groups. Only sputum eosinophilia remained significantly associated with reversibility across the 
spectrum of respiratory disease in smokers with airway complaints.
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Background
Smoking causes chronic airway complaints in a significant 
proportion of the population [1]. The primary care physi­
cian and respiratory nurse specialist are generally the first 
to assess patients with a chronic cough, complaints of dys­
pnea or sputum production [2]. Ideally, common causes 
like COPD and asthma are differentiated by spirometry 
with reversibility testing, performed and interpreted by 
sufficiently trained staff [3,4].
Sputum induction is a valid and noninvasive method to 
assess airway inflammation, which is Patients with COPD 
[5,6]There is evidence of different cellular and cytokine 
activation in induced sputum from smoking compared 
with nonsmoking asthmatics; a positive relationship is 
apparent between smoking history, neutrophilic airway 
inflammation and deteriorating lung function in smoking 
asthmatics [7]. In mild asthmatics, bu t also in other respi­
ratory patients, sputum, bronchoalveolar lavage and 
blood measure different compartments of inflammation 
[8]. The proportion of eosinophils in sputum is a more 
accurate marker of asthmatic airway inflammation than 
the proportions of blood eosinophils [9], suggesting a 
predominantly local systemic inflammatory process of 
lung tissue.
Patients with COP show significantly higher percentages 
of neutrophils and levels of soluble TNF receptor p55 
(sTNF-R55) and the chemokine interleukin IL-8 in spu­
tum as compared with control subjects [10]. Both neu­
trophils and eosinophils seem to be activated by IL-8 
[11,12], which seems to be closely related with the degree 
of airflow obstruction [13]. In the circulation, increased 
levels of inflammatory markers such as lipopolysaccha- 
ride binding protein (LBP) and sTNF-R55 have been 
reported [14].
We studied the relation between patterns of inflammation 
and clinical diagnosis in primary care patients. By careful 
history taking (symptoms, smoking behaviour, atopic his­
tory) and measuring lung function including reversibility 
in smoking patients with respiratory complaints, we dis­
tinguished four clinical diagnosis groups: COPD (accord­
ing to GOLD [1]), asthma, chronic bronchitis (GOLD 0) 
and a control group of 'healthy smokers' (no respiratory 
symptoms, no obstruction). Aim of the study was not to 
change or confirm these clinical diagnoses, but to reveal 
any specific inflammatory patterns underlying disease 
groups. We also tested what factors were associated with 
eosinophilia, a possible target for treatment.
Methods 
Patient selection
The COOPT-study (COPD Q n Primary Care Treatment) 
recruited a heterogeneous group of (current or past)
smokers with mild to moderate COPD and chronic bron­
chitis from 46 general practices in the Netherlands [15]. 
Reversibility was no t an exclusion criterion, bu t any his­
tory of atopy, eczema or asthma was. Patients with an 
FEV1 between 40-88%  of predicted values were included; 
m ean post-BD FEV1 was 66% of predicted value (ranging 
from GOLD 0 to GOLD 3). A subgroup of the COOPT- 
population underwent sputum induction at the lung 
function laboratory of University Hospital Maastricht; 
only those in whom sputum induction was successful 
were included in analyses. In addition, we recruited smok­
ing control patients with asthma features (atopy, eczema, 
previous recurrent episodes of wheezing, breathlessness, 
chest tightness, and/or cough and variable airflow 
obstruction to inhaled salbutamol) and smokers without 
respiratory complaints ('healthy smokers') from general 
practices not taking part in the COOPT-study, who subse­
quently also underwent sputum induction. Respiratory 
symptoms, smoking behaviour, atopic features, careful 
clinical history taking, and lung function measurements 
including reversibility determined the diagnostic category 
into which subjects were classified, analogue to earlier 
studies [10,14]. Patients with COPD thus had an absence 
of atopic features, but a smoking history of at least 15 
packyears and a persistent obstruction, while patients 
with asthma had an atopic history and a variable obstruc­
tion, with a recorded reversibility >10%. Chronic bron- 
chitics had chronic respiratory complaints for at least 3 
m onths during the past two years bu t no obstruction, 
while 'healthy smokers' had a considerable smoking his­
tory but no chronic respiratory complaints.
During the recruiting phase, considerable effort was put 
into age matching, since age has been shown to affect spu­
tum induction results [15]. Exclusion criterion was any 
inhaled or oral corticosteroid use in past six weeks, since 
this is known to possibly influence sputum induction 
results and underlying systemic inflammatory patterns 
[18,19]. Furthermore, increased respiratory complaints or 
signs of respiratory tract infection during four weeks pre­
ceding the study was considered a criterion for exclusion. 
The control subjects lived in the same geographical area as 
the patient population. The study protocol was approved 
by the Medical Ethics Committee at the University Hospi­
tal Maastricht, and written informed consent was 
obtained from all subjects.
Pulmonary function testing and blood and sputum 
sampling
Trained lung function technicians measured FEV1 before 
and 15 minutes after inhalation of fi-agonist (salbutamol 
400 ug) via a metered-dose inhaler, using a spirometer 
(Masterlab; Jaeger, Wurzburg, Germany), according to 
ATS-criteria [2]. Before sputum induction (8:00 to 10:00 
A.M.) took place, blood samples were collected in evacu­
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ated blood collecting tubes containing ethylenediamine- 
tetraacetic acid (EDTA; Sherwood Medical, St. Louis, MO). 
Plasma samples were stored at -80°C until analyzed. Spu­
tum was induced according to a procedure reported else­
where [12]. Briefly, subjects inhaled 3% hypertonic saline, 
nebulized via an ultrasonic nebulizer (NEB2000; TEFA- 
Portanje, Woerden, The Netherlands) during three 7- 
minute periods. To minimize saliva contamination, sub­
jects were instructed to mouthwash thoroughly with 
saline solution before expectoration. The collected spu­
tum was pooled and kept at 4°C for not more than 2 
hours prior to further processing. The volume of the 
pooled sputum (without selection of sputum plugs) was 
recorded, and an equal volume of 0.2% dithiothreitol 
(DTT; Sputolysin; Calbiochem, La Jolla, CA) was added. 
The samples were then mixed gently by a vortex mixer and 
incubated for 20 minutes at room temperature to ensure 
complete homogenization. Cell-free supernatants were 
frozen at -80°C until subsequent analysis. The total cell 
count and cell viability were assessed using a standard 
hemocytometer (Coulter Z1; Coulter Electronics, 
Mijdrecht, The Netherlands) and by trypan blue exclu­
sion, respectively. Cytospins were stained according to the 
May-Grunwald-Giemsa method. An observer who was 
blinded to the clinical characteristics carried out the differ­
ential cell counts, counting 500 nucleated cells. The num ­
bers of squamous cells were substracted, and the 
differential cell counts were expressed as corrected per­
centages. A sample was considered adequate if the slides 
contained 15% or less squamous epithelial cells.
Measurements o f  inflammatory mediators in sputum and 
plasma
sTNF-R were measured in sputum supernatant and 
plasma using specific sandwich enzyme-linked im m uno­
sorbent assay (ELISA) as described earlier [20,21], which 
were not affected by presence of TNF-a [22], indicating 
measurement of total amounts of sTNF-R55 and sTNF- 
R75 (free and bound to TNF-a). Total TNF-a (free TNF-a 
and TNF-a bound to sTNF-R) was determined using a
Tab le  1: Population characteristics. Figures are m eans (S D ).
commercially available ELISA (HyCult Biotechnology BV, 
Uden, The Netherlands). IL-8 and LBP levels were deter­
mined using specific sandwich ELISA as described previ­
ously [19,23,24]. The lower detection limit was 60pg/ml 
for sTNF-R55, 30pg/ml for sTNF-R75, 20pg/ml for total 
TNF-a, 8 pg/ml for IL-8 and 1ng/ml for LBP. The presence 
of DTT resulted in less than 5% inhibition of the detection 
of sTNF-R55, IL-8 and LBP and less than 10% inhibition 
in case of sTNF-R75 and total TNF-a fraction, indicating 
that DTT has little or no effect on the assays used in this 
study (data not shown).
Statistical analysis
Results are presented as mean ± SD for normally distrib­
uted variables and median (range) otherwise. Crossec- 
tional data analysis was performed on the four diagnostic 
categories: COPD, asthma, chronic bronchitis and 
'healthy smokers'. Cell patterns and inflammatory media­
tors in induced sputum were analysed, and compared 
with inflammatory mediators in blood samples. Cut-off 
point for sputum eosinophilia was > 3% [22]. Patterns of 
inflammatory markers per diagnosis and clinical factors 
associated with eosinophilia were analyzed in an adjusted 
backward regression model, the differences expressed in 
odds ratios (OR) with 95% confidence intervals. A p value 
of less than 0.05 denotes the presence of a significant sta­
tistical difference. (Statistical Package for the Social Sci­
ences, version 11.0 for Windows; SPSS Inc., Chicago, IL).
Results
Table 1 shows the population characteristics, indicating 
moderate obstruction (average FEV1 post BD 59% pre­
dicted; GOLD 2) and highest level of packyears in patients 
with COPD, while asthmatics have fewer packyears and 
clinically relevant reversibility. Healthy smokers and 
chronic bronchitis (GOLD 0) patients express normal 
lung function despite considerable packyears, while 
females are overrepresented among healthy smokers, 
especially compared to COPD. No significant differences 
with regard to age appear between diagnosis groups.
COPD n = 17 Asthma n = 11 CB n = 14 HS n = 17
Age (range) 61.4 (41-74) 57.6 (36-73) 53.9 (34-72) 54.6 (42-64)
Gender (f/m) 2/15* 3/8 5/9 11/6*
Smoking status (former/ 6/11 5/6 4/10 7/10
current)
Packyears 48.4* (29) 23.1* (20) 33.5 (18) 32.3 (13)
FEV|/FVC postBD 0.56 (0.13)* 0.70 (0.17) 0.73 (0.2) 0.77 (0.22)*
FEV, postBD (%pred) 59.0* (17) 82.1 (17) 100.7* (17) 103.9* (19)
BD-Reversibility (A FEV l 3.5 (9) 12.1* (7) 4.5 (5) 4.9 (4)
%pred)
*:p < 0.05 using A N O V A analysis.
CB = chronic bronchitis; HS = healthy smokers
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In table 2 the inflammatory patterns in different diagnosis 
groups are presented. Univariately, COPD was associated 
with sputum neutrophilia (OR 1.09 [1.04-1.15]), ele­
vated IL-8 (OR 1.4 [1.1-1.7]), sTNF-R55 (OR 1.005 [1.0­
1.01]) and sTNF-R75 (OR 1.005 [1.0-1.01]) in sputum, 
and raised levels of IL-8 (OR 2.5 [1.01-6.0]), sTNF-R55 
(OR 7.6 [1.6-35.1]), sTNF-R75 (OR 10.2 [2.2-47.8]) and 
LBP (OR 1.1 [1.04-1.25]) in plasma,. Asthma patients 
showed a positive association with sputum eosinophils 
(OR 1.3 [1.05-1.5]), and inversely with sputum neu­
trophils OR 0.96 [0.9-0.99]), while patients with chronic 
bronchitis (GOLD 0) showed raised levels of lymphocytes 
(OR 1.5 [1.1-1.9]) in sputum, and significantly lower lev­
els of sTNF-R55 (OR 0.1 [0.02-0.7]) and sTNF-R-75 in 
plasma (OR 0.1 [0.2-0.8]). Healthy smokers showed a 
lowered LBP (OR 0.8 [0.7-0.95]) in plasma, but no other 
significant relations. In table 3 these (positive or negative) 
univariate patterns of inflammation are indicated by + 
and -, while ++ and -  indicate multivariate patterns of 
(positive or negative) significant relations.
Multivariate associations
Multivariately, COPD remained significantly associated 
with sTNF-R55 in sputum (OR 1.01 [1.001-1.01]) and 
raised plasma-LBP (OR 1.2 [1.04-1.37]), while HS 
expressed significantly lowered plasma-LBP (OR 0.8 
[0.72-0.95]) by contrast (see Table 3). Asthma was char­
acterized by higher sputum eosinophilic counts (OR 1.3 
[1.05-1.54]), while CB (GOLD 0) showed a significantly 
higher proportion of lymphocytic counts in sputum (OR
1.5 [1.12-1.9]).
Clinically, sputum eosinophilia (> 3%) [22] was the only 
variable significantly associated with reversibility (OR 1.2
[1.04-1.36]) after adjusting for smoking, lung function, 
age, gender and allergy in the backward regression model. 
Figure 1 illustrates that sputum eosinophilia occurs across 
the spectrum of respiratory disease, independent from 
degree of obstruction; post-bronchodilator FEV1s are 
between 4-0110%  of predicted. The independent rela­
tionship between reversibility and sputum eosinophilia 
was somewhat stronger when choosing the more recently 
proposed higher cut-off point of 4.6% [14]: OR 1.3 [1.0­
81.53].
Discussion
In this study we demonstrate that distinct inflammatory 
patterns in sputum and blood are discernable in clinical 
diagnosis groups of respiratory disease in smokers with 
airway complaints. Univariately, COPD was associated 
with sputum neutrophilia, and raised levels of IL-8, sTNF 
R55 and sTNF R75 in both sputum and plasma, and an 
increased level of plasma LBP. By contrast, chronic bron- 
chitics (GOLD 0) were associated with raised lymphocytes 
and lowered sTNF R55 and sTNF R75 plasma-levels. 
'Healthy smokers' showed a lowered plasma-LBP level, 
while asthma patients showed a pattern of lowered neu­
trophils bu t high eosinophils. Multivariately, COPD 
remained associated with raised sputum-sTNF R55 and 
plasma-LBP, in contrast with a significantly and inde­
pendently lowered plasma-LBP in 'healthy smokers'. In 
asthma patients, only the high level of sputum eosi­
nophilic inflammation remained independently associ­
ated, which underlines the difference between the sputum 
and plasma compartments in differentiating disease. 
Chronic bronchitics (GOLD 0) retained a relative pre­
dominance of lymphocytic inflammation in plasma com­
pared to the other clinical diagnosis groups, which could
Tab le  2: P atterns o f in flam m a to ry  m arkers  w ith in  clinical diagnosis groups. Results are expressed in m eans (S D ).
Compartment Inflammatory markers COPD Asthma CB HS
Sputum cell counts Volume (ml) 6.7 (0.86) 6.9 (0.95) 6.8 (0.93) 3.4 (0.42)
Total counts ( l0 6 
cells/ml)
4.3 (0.80) 2.3 (0.91) 2.0 (0.5) 4.0 (0.99)
Neutrophils (%) 81.3* (12.2) 49.0* (25.2) 56.6 (23.2) 62.4 (16.5)
Eosinophils (%) 1.8 (3.7) 20.2*  (30.0) 1.3 (1.5) 0.8 (1.1)
Lymphocytes (%) 0.7 (1.2) 1.8 (2.7) 3.4* (3.4) 0.9 (0.8)
Macrophages (%) 16.8* (10.5) 29.1 (24.0) 38.6 (21.9) 35.9 (15.6)
Sputum mediators sTNF-R55 (pg/ml) 658.2* (785.0) 64.4 (14.6) 97.2 (72.7) 169.2 (135.5)
sTNF R-75 (pg/ml) 222.7* (289.3) 64.3 (53.9) 87.6 (68.1) 84.6 (68.8)
LBP (ng/ml) 10.1 (1 1.2) 9.3 (6.3) 7.9 (8.3) 5.3 (5.7)
IL-8 (ng/ml) 5.5* (3.9) 2.6 (3.2) 2.7 (1.7) 2.4 (1.5)
Plasma mediators sTNF-R55 (ng/ml) 2.0* (0.5) 1.6 (0.4) 1.5* (0.3) 1.8 (0.4)
sTNF-R75 (ng/ml) 2.0* (0.4) 1.7 (0.5) 1.4* (0.3) 1.5 (0.4)
LBP (|ig/ml) 28.2* ( 11.2) 20.0 (4.7) 22.8 (6.5) 17.6* (4.5)
IL-8 (pg/ml) 7.7* (1.3) 7.1 (0.3) 7.2 (0.6) 7 (0.0)
(*indicates statistical difference from total, p < 0.05, using univariate regression analysis) CB = chronic bronchitis; HS = healthy smokers
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Compartment Inflammatory markers COPD Asthma CB HS








Plasma mediators sTNF-RSS (ng/ml) + -
sTNF-R?S (ng/ml) + -
LBP (|ig/ml) +/++ - /-
IL-8 (pg/ml) +
(+ indicates positive univariate significance; - indicates significant negative univariate relation; ++ indicates positive multivariate significance; -­
indicates negative multivariate significance) CB = chronic bronchitis; HS = healthy smokers
point at a subpopulation of T cells in this phenotype. The 
considerably raised sputum-sTNF R55 and R75 in COPD- 
patients is in line with earlier studies of inflammation 
[10,14], pointing at structural changes in the airway wall 
as a result of prolonged and ongoing smoking-induced 
inflammation. Interestingly, the high levels of plasma- 
LBP but no t in sputum of COPD-patients suggests a blood 
born systemic component, which may open a possibility
for disease differentiation. By contrast, the lowered 
plasma-LBP in 'healthy smokers' is a new finding that war­
rants further investigation, possibly pointing at genetic 
differences in the inflammatory cascade. The clear distinc­
tion in inflammatory patterns between 'at risk' (GOLD 0) 
and COPD patients is an intriguing finding, which con­
firms earlier findings from the longitudinal Copenhagen 
City Heart Study, in which a gradual development from
Figure!
Sputum eosinophilia (> 3%) occurs in a wide range of patients with airway obstruction (IA ) and is associated with bronchodila- 
to r reversibility (IB).
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GOLD 0 to GOLD 1 or higher levels of obstructive disease 
could no t be demonstrated [23]. It now seems justified on 
the basis of inflammatory patterns to make a clear distic- 
tion between chronic bronchitis (GOLD 0) and 'true 
COPD' (i.e. GOLD 1,2,3 and 4).
Furthermore, eosinophilia occurs across the spectrum of 
clinical diagnosis groups, remaining associated with 
reversibility, in contrast with all other clinical variables. It 
seems that the recent ATS/ERS Standards for the diagnosis 
and treatment of COPD recommendation to 'treat 
patients showing a clinically relevant reversibility as asth­
matics' is in line with these findings [2]. Fabbri and cow­
orkers [14] found that despite fixed airflow obstruction 
similar to COPD, a history of asthmatic symptoms 
remains closely related to eosinophilic inflammation. 
Indeed, they concluded that different inflammatory path­
ways do exist in patients with fixed airway obstruction. 
Airway inflammation with eosinophils has been reported 
to occur no t only in asthma but also in other airway dis­
eases such as chronic cough, allergic rhinitis and COPD 
[27]. Sputum eosinophilia has been associated with an 
accelerated decline in FEV1 and the development of 
COPD [28]. Induced sputum analysis allows detection of 
sputum eosinophilia in clinical practice [29], which is 
clinically im portant since it may be linked to corticoster­
oid response in COPD [22,30,31]. By contrast, there is 
increasing evidence that an absence of sputum eosi- 
nophilia is associated with steroid resistance [32,33]. The 
proportion of eosinophilic COPD seems to be limited, 
and of debatable clinical relevance: 4 out of 17 (24%) 
COPD-diagnoses when using the > 3% cut-off for sputum 
eosinophilia, but only 1 out of 17 (6%) when using the 
more recently proposed cut-off of 4.6% [14]. In our 
chronic bronchitis group, we found only 1 out of 14 (7%) 
when using the cut-off of 4.6%, while the group of 
'healthy smokers' expressed no eosinophilia.
Through multivariate analysis confounding differences in 
baseline were corrected for, and insight was achieved into 
the relative importance of each variable; most previous 
diagnostic studies have not used such statistical tech­
niques. Furthermore, careful age matching during the 
recruitment phase resulted in sufficiently comparable 
diagnosis groups, since age is known to affect sputum 
induction results, especially neutrophilia [15]. Based on 
the same reasoning, we excluded the use of inhaled or sys­
temic steroids in the six weeks preceding study, since this 
would likely affect levels of inflammatory cells and medi­
ators in sputum and plasma [18].
Conclusion
Based on clinical diagnoses, patterns of inflammatory 
markers in blood plasma and sputum were discernable in 
clinical diagnosis groups of respiratory disease in smokers
with airway complaints. Multivariately, a smaller set of 
variables remained significantly associated, which opens 
the possibility to test predictive values of these variables in 
larger populations. COPD (GOLD 2) and so-called 
'healthy smokers' showed consistent opposite associa­
tions with plasma LBP, while chronic bronchitics (GOLD 
0) showed relatively predominant lymphocytic inflam­
m ation compared to other diagnosis groups. Eosinophilia 
remained significantly associated with reversibility across 
the spectrum of respiratory disease in smokers with airway 
complaints, while other clinical characteristics were not.
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